Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 11 points (0.1%) at 16,218 as of Tuesday, Feb. 25, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,600 issues advancing vs. 1,298 declining with 186 unchanged. The Health Care sector currently sits up 0.6% versus the S&P 500, which is up 0.2%. On the negative front, top decliners within the sector include Humana ( HUM), down 1.9%, and UnitedHealth Group ( UNH), down 0.8%. Top gainers within the sector include InterMune ( ITMN), up 159.0%, Grifols ( GRFS), up 3.0% and Boston Scientific ( BSX), up 2.2%. TheStreet would like to highlight 3 stocks pushing the sector lower today: 3. Fresenius Medical Care AG & Co. KGaA ( FMS) is one of the companies pushing the Health Care sector lower today. As of noon trading, Fresenius Medical Care AG & Co. KGaA is down $1.96 (-5.4%) to $34.32 on heavy volume. Thus far, 200,033 shares of Fresenius Medical Care AG & Co. KGaA exchanged hands as compared to its average daily volume of 156,000 shares. The stock has ranged in price between $34.20-$34.61 after having opened the day at $34.44 as compared to the previous trading day's close of $36.28. Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, operates in the field of dialysis care and dialysis products for the treatment of end-stage renal disease. Fresenius Medical Care AG & Co. KGaA has a market cap of $21.7 billion and is part of the health services industry. Shares are up 2.0% year-to-date as of the close of trading on Monday. Currently there are 2 analysts that rate Fresenius Medical Care AG & Co. KGaA a buy, no analysts rate it a sell, and 8 rate it a hold. TheStreet Ratings rates Fresenius Medical Care AG & Co. KGaA as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, increase in net income, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Fresenius Medical Care AG & Co. KGaA Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.